Acetylcholinesterase pre-mRNA is susceptible to alternative splicing. Myasthenia gravis has been shown to be associated with the expression of the readthrough transcript (AChE-R), which, unlike the normal "synaptic" transcript (AChE-S) is not tethered to the post-synaptic membrane, but is a soluble monomer in the synaptic cleft. In rats with experimental autoimmune myasthenia gravis (EAMG), inhibition of production of AChE-R using antisense is associated with a significant reduction in synaptic expression of AChE-R mRNA and protein, with improved muscle strength and stamina and increased survival. Synaptic AChE does not appear to be significantly affected by the induction of EAMG or treatment with antisense to AChE-R. Monarsen (EN101) is a synthetic 20-base antisense oligodeoxynucleotide directed against the human AChE gene. It is modified to achieve stability for oral administration. Sixteen patients with seropositive myasthenia gravis who were responsive to pyridostigmine were withdrawn from it and treated with Monarsen. Fourteen patients experienced a clinically significant response. In some, the improvement was dramatic. Although the dose of pyridostigmine was not optimized before the study, the majority of responders achieved better Quantitative Myasthenia Gravis scores than on pyridostigmine. The response of an individual muscle group to Monarsen was related to the degree of deterioration following the withdrawal of pyridostigmine. Cholinergic side effects were conspicuous by their absence. Monarsen is now being investigated in a phase II study.
Introduction
Myasthenia gravis is a well-characterized neurological autoimmune disease in which the loss of functional receptors result in deficits in cholinergic neurotransmission with consequential weakness and fatigability of voluntary muscle. Nicotinic acetylcholine receptor (nAChR) and acetylcholinesterase (AChE) functions are closely inter-related. 1 AChE in humans is encoded by a single gene located on chromosome 7q22, but multiple forms of AChE protein arise from alternative splicing of exons at the 3 end of the open reading frame. The principal transcript in muscle is AChE-S, the synaptic form, which is formed by splicing exon 4 to exon 6. Continuous transcription from exon 1 through to exon 6, including intron 4 yields the "readthrough" transcript. 2 Acute exposure to anticholinesterases results in increased production of the readthrough transcript (AChE-R) which differs from the synaptic variety in the structure of the C-terminal sequence. 3 While both forms of the enzyme are able to hydrolyze ACh, AChE-S forms multimers and associates with the postsynaptic membrane through the proline-rich PRiMA anchor. AChE-R, in comparison, lacks the carboxylterminal cysteine that is required for binding and is a soluble monomer. 4 
Different AChE Transcripts Have Different
Effects at the Synapse
In the immediate aftermath of anticholinesterase exposure, elevated AChE-R attenuates initial hyperexcitation. 5 There are data from a variety of settings suggesting that continued accumulation of AChE-R may prolong cholinergic impairment by increasing adhesive 6 and morphogenic activities of AChE. 7 Accumulation of AChE-R is also associated with structural muscle changes. 8 It has been hypothesized that homologies between AChE and the cell-adhesion proteins gliotactin, glutactin, and the neurexins may be the basis for its morphogenic functions. 3 Transgenic mice that overexpress AChE-S have a range of synaptic abnormalities, including increased numbers of vesicles at the presynaptic site and enlarged neuromuscular junctions (NMJs) with either deeper or shallower synaptic clefts than normal. 9 Physiological studies on the transgenic hemidiaphragm demonstrate marked fatigue arising from both fading neurotransmission and muscle mechanical failure. Increased quantal content also results in abnormal synaptic responses. 10 AChE variants may play a wider role outside the NMJ; transgenic mice that overexpress AChE-R or AChE-S show changes suggesting that excess AChE-R attenuates and excess AChE-S intensifies neurodegeneration in the brain, suggesting that AChE-R serves as a modulator that may have a role in preventing acute synaptic stress from generating chronic changes.
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The Readthrough Transcript in Experimental Autoimmune Myasthenia Gravis
The pathophysiological relevance of the readthrough transcript was studied in rats with experimental autoimmune myasthenia gravis (EAMG) induced by subcutaneous injection of Torpedo ACh receptor. AChE-R could be identified in low levels in the blood of healthy rats, but much higher levels were identified in EAMG animals. EAMG rats showed a predicted drop in nAChR which correlated with disease grade. Immunocytochemistry with a polyclonal serum to AChE-R showed evidence of protein in some but not all fibers, with a cytoplasmic distribution characteristic of this isoform, in contrast to the membrane-associated clustering typical of AChE-S. AChE-S level of expression was similar between EAMG and control animals. In situ hybridization showed only weak and diffuse labeling for AChE-R mRNA in healthy rats where as EAMG rats showed pronounced punctate staining for AChE-R mRNA, suggesting selective overexpression in muscles. 12 Antisense Oligonucleotide Selective Suppression of AChE-R Production in Rats with Experimental Autoimmune Myasthenia Gravis Antisense oligonucleotides are short synthetic stands of modified DNA or RNA designed to hybridize within the cell with target-specific mRNA by Watson-Crick base pairing. Binding activates RNAses that degrade the mRNA-antisense complex, thus blocking synthesis of the protein encoded by the mRNA sequence and releasing the antisense to bind to a further strand of mRNA, creating a recycling antisense mechanism.
It was hypothesized that in EAMG, the soluble overexpressed AChE-R might increase degradation of ACh in the synaptic cleft resulting in muscular weakness. To test this hypothesis, one author (H.S.) constructed antisense which selectively destroys AChE-R (EN101, Monarsen). Monarsen is a 20-mer oligonucleotide, chemically modified by incorporating 2'oxymethyl groups in the last three nucleotides at its 3 end, which binds to a coding sequence common to all isoforms of AChE. 13 Since the AChE-R mRNA transcript is longer and less G/C rich than AChE-S, it intrinsically less stable and more sensitive to Monarsen. Monarsen is active both intravenously and orally. 12 One day after Monarsen administration to EAMG rats, muscle immunohistochemistry demonstrated a significant reduction in muscle AChE-R without any significant reduction in AChE-S. AChE-R mRNA was reduced to the limits of detection by Monarsen. This confirms the specificity of transcript destruction, although Monarsen targets all transcripts.
The physiological consequences of AChE-R reduction was assessed in Monarsen-treated EAMG rats by measuring compound muscle action potentials (CMAPs) from gastrocnemius. EAMG rats demonstrated decrement during repeated stimulation that was never found in control animals. Intraperitoneal neostigmine corrected the deficit in EAMG rats. Monarsen treatment had no effect on control animals but corrected CMAP in EAMG animals in a dosedependent manner with an accompanying improvement in ambulation and stamina when tested on a treadmill. This implies that AChE-R has a causal role in NMJ dysfunction in this model. 12 There were differences between EAMG animals' responses to pyridostigmine and Monarsen. The onset of response to pyridostigmine was more rapid, whereas the duration of action of Monarsen was greater. Oncedaily doses of Monarsen maintained stable CMAPs over 96 h without the fluctuations arising from the short duration of action of pyridostigmine. Daily treatment for 4 weeks demonstrated improved survival, clinical status, and stamina among animals receiving Monarsen, 12 though the poor survival of EAMG rats receiving once-daily pyridostigmine might have improved with increased dosing. Single-fiber electromyography (EMG) studies also demonstrated improvement in mean jitter and blocking for 24 h, which was more efficient than pyridostigmine.
These results suggest that in EAMG the initial response to anticholinesterases is to slow ACh destruction compensating for the reduced AChR number. The resulting increased AChE-R production then increases catalysis of ACh, limiting the efficacy of anticholineserases. The induction of AChE-R mRNA is a rapid process, being well underway within 30 min of exposure to anticholineserases. 5 
Cholinergic Influences on the Immune System
Over many years. Tracey and colleagues have elucidated what has become known as the cholinergic anti-inflammatory pathway, in which the stimulated vagus nerve by releasing ACh reduces the release of TNF and other cytokines by macrophages in a number of inflammatory settings. 15, 16 This process is mediated by the nicotinic acetylcholine receptor 7, which is expressed on macrophages.
17 AChE inhibitors have been shown to suppress lymphocyte proliferation and pro-inflammatory cytokine production, as well as extracellular esterase activity. 18 The influence of the cholinergic system extends to thymic function. AChE-R transgenic mice have smaller thymic medullas compared to strain-matched controls. They also show increased number of CD4 + CD8 + cells, which are considerably more resistant in vitro to apoptosis than normal thymocytes, indicating that AChE-R overexpression interferes with thymic differentiation mechanisms possibly including positive selection. 19 Monarsen treatment suppressed the levels of the proinflammatory cytokines IL-1 and IL-6 in the central nervous system neurons of stressed cynomolgus monkeys 20 and reduces the severity of experimental autoimmune encephalomyelitis. 19 These data suggest that the benefits of Monarsen in EAMG may not solely be a consequence of modification of synaptic function.
AChE Transcripts in Human Myasthenia Gravis
Differentiation between AChE transcripts on polyacrylamide gels stained for AChE activity depends on greater speed of migration of the monomeric AChE-R than the tetrameric AChE-S. Glycosylation and carboxyl-terminal sequence differences may also influence protein separation, such that definitive studies on transcripts in humans is lacking. Serum from approximately half of patients with myasthenia gravis contains fast-migrating AChE not found in healthy humans and other neurological diseases. Although data are from limited numbers of patients, there did not appear to be any correlation between AChR antibody titers and total serum AChE and the presence of AChE-R in the serum of myasthenic patients. 12 
Monarsen in Autoimmune Myasthenia Gravis
In light of the efficacy of Monarsen in EAMG and the evidence that AChE-R is associated with myasthenia gravis in humans, a phase Ib study of Monarsen in myasthenia gravis was undertaken. The study was designed as a two center, non-placebo-controlled, openlabel study of 16 patients with myasthenia gravis. The dose of Monarsen was selected from efficacy studies carried out in EAMG rats in which 500 µg/kg reversed muscular weakness. Based on these studies escalating doses of 10 µg/kg, 50 µg/kg, and 150 µg/kg were selected with a maximum dose of 500 µg/kg. Preclinical animal toxicology studies were performed in mouse, rat, and cynomolgus monkey using oral and i.v. doses of up to 5000 µg/kg/day-10 times the dose intended for human use-without any drug-related toxicity being identified.
The study was carried out with consent from the Medicines Control Agency in the UK and with consent of the ethics committees of Hope Hospital, UK, and the Hadassah University Hospital, Jerusalem. The protocol was designed and the trial executed under the scrutiny of an independent advisor, Prof. John Newsom-Davis. The following inclusion criteria were selected:
Symptomatic myasthenia gravis with class II or higher disease on the Myasthenia Gravis Foundation of America (MGFA) classification. Aged 18-75. Seropositive for AChR, or with an EMG decremental response of at least 20% in the amplitude of the 5th summed muscle action potential, compared with the first when stimulated at 3-5 Hz. Receiving at least 180 mg pyridostigmine per day. Stable concomitant steroid or other immunosuppressive treatment for at least 3 months. Clinical condition stable for at least 3 months. Normal hepatic, renal, thyroid, coagulation, and blood counts. Women of childbearing age required to agree to use effective contraception during the course of the study and for the following 3 months.
The following exclusion criteria were selected:
Acute respiratory failure, major bulbar dysfunction, or major weakness responsible for discontinuation of physical activity over the one month prior to screening. Exclusively mild ocular disease. Patients were admitted to the hospital on the evening before Day 1, to begin a 12-to 18-h washout from pyridostigmine. On Day 1, patients started on a single Monarsen dose of 10 µg/kg at time 0, followed by 50 µg/kg 4 h after the first dose, and 150 µg/kg 8 h after the second dose. For the next 3 consecutive days, patients received a single dose of 500 µg/kg given 24, 48, and 72 h after the first dose. Physical examination, including (Quantitative MG Score) (QMG) scoring, was carried out before the first dose of Monarsen was given, and 2 and 4 h after each dose on day 1, and 2, 6 and 10 h after each dose on days 2-4. A washout period commenced on day 5, during which QMGs were performed at 4-h intervals. Pyridostigmine was reintroduced at the request of the patient when, in their judgment it was required. A follow-up assessment was made after 7, 14, and 28 days. Immunosuppressive medications were continued unaltered during the whole experimental period.
Each day (4 days of medication and 2 days of washout from Monarsen), patients underwent a full physical examination, blood sampling for blood count and coagulation, biochemistry, urinalysis, and ECG. They were questioned about adverse events and concomitant medications. After discharge, they had these evaluations at weeks 1, 2, and 4.
The adverse events data were collected individually and summarized by body system and preferred terms within a body system. If the same adverse event occurred on multiple occasions, the highest severity and least complimentary relationship with Monarsen was to be assumed.
The primary efficacy parameter was the QMG. This score summarizes 10 measurements: fatigue in each limb (4) and neck (1), swallowing rate (1), speech/counting (1), power in hands (2), and respirometry (1); and 3 clinical observations: double vision, ptosis, and facial weakness. The total score maximum is 39.
Sixteen patients were enrolled, eight of each gender. One patient failed to respond to Monarsen and took intermittent doses of pyridostigmine, a major protocol violation, and therefore was not included in the efficacy analysis. All sixteen patients were included in the safety analysis.
Results

Patient Demographics
Sixteen patients were enrolled in the study. The mean age was 57.6 ± 7.9 years. Mean duration of myasthenia gravis was 17.3 ± 10 years (range 1.3-32.8). The disease duration and severity, thymectomy status, and anti-AChR antibody titer data are shown in TABLE 1.
The distribution of disease severity is shown in TABLE 2. Most patients were more affected than the minimum entry criterion of grade II disease.
Efficacy Results
The primary efficacy parameter was total QMG. Analysis consisted of a comparison with baseline (day 1, pretreatment) QMG (TABLE 3) . Since three doses of Monarsen were given on the first day, each QMG was considered separately. For subsequent days, daily QMGs were calculated by averaging the total QMG over the entire day. Changes from base line were analyzed using the Student's t-test. Additionally, the nonparametric Wilcoxon signed rank statistic was also analyzed. Statistical significance was determined at the 0.05 level. All patients had an improved QMG on day 4 in comparison with base line (TABLE 4). The overall improvement by day 4 was 6.13 ± 4.5 QMG points, or an overall 46.5 ± 30.9% increase in score. The daily change in QMG expressed as points and percentage change are shown in TABLES 4 and 5. The changes were statistically significant from day 2 onward.
Total QMG measurement may underestimate changes in muscle power, as the total value includes muscle groups that may not be affected by muscle weakness. Further analysis was therefore carried out utilizing the approach developed for the randomized, double-blind trial of prednisolone alone or in combination with azathioprine. 21 The mean of the three lowest baseline ratios for which normal is defined, that is, the worst functioning muscle groups at base line, was compared to the ratios of the same three QMG components at each daily visit. Components included in this analysis with defined normal limits in the QMG included: double vision, ptosis, right and left arm outstretched, vital capacity, right hand grip, left hand grip, raising head, right and left leg outstretched. Statistically significant results were found from days 2-6. The results of this analysis are presented TABLE 6.
The relationship between pyridostigmine and Monarsen responsiveness was assessed by grouping individual muscles according to the degree of deterioration in muscle power on withdrawal of pyridostigmine at the start of the study. Muscles were divided into three groups; nondippers, with deterioration in power of less than 10%, dippers of 25-50%, and those dipping by greater than 50%. The results are shown in FIGURE 1. The greater the deterioration on pyridostigmine withdrawal, the greater the responsiveness to Monarsen. Pyridostigmine doses were not specifically optimized before the start of this study. Nevertheless, there is the impression that muscle power on Monarsen appeared to be greater than on pyridostigmine. After 4 days on Monarsen treatment, QMG was still continuing to rise.
Since this is a non-placebo-controlled, open-label study, variables were examined that were considered less likely to be susceptible to the placebo effect. Analysis of the percentage change in the vital capacity component of the QMG demonstrated a progressive improvement in vital capacity over the course of the study, achieving statistically significance from day 3 (TABLE 7) . Assessment of the swallowing rate for 4 oz water showed a progressive deterioration from pyridostigmine withdrawal, until shortly before the second dose of Monarsen, followed by a progressive improvement in swallowing rate over the remaining course of the study (TABLE 8) .
Evaluation of Response
The investigators and patients independently evaluated the clinical response. TABLE 9 describes the results. More than 90% of investigators and patients felt that there had been an improvement in symptoms while receiving Monarsen.
Efficacy Conclusions
Of the 15 patients, all had improvement in QMG on day 4 compared with base line. The overall mean change from base line of total score was 6.13 ± 4.5 QMG points, and the overall mean percent improvement from base line was 46.5%. These were statistically significant when compared to the hypothesis of no change (P < 0.01).
The QMG improved steadily over time, and was statistically significant for days 2-6 (P < 0.01).
The improvement in the QMG appeared to be dosedependent, though a delayed onset of action would give rise to similar findings. Statistical significance was obtained after administration of 150 µg/kg and 500 µg/kg of Monarsen (P = 0.04 and 0.003, respectively).
Ninety-four percent of the patients reported improvement of symptoms as well as general well-being with Monarsen compared with pyridostigmine. One patient failed to respond to Monarsen while remaining very responsive to pyridostigmine.
Adverse Events
A range of adverse events were described by participants in the study (TABLES 10 and 11). All the adverse events resolved without treatment or need to discontinue Monarsen. All but two of the adverse events were considered to be mild. One event of fever was moderate and one of hypertension was considered to be severe. Neither of these events was considered related to the study drug.
Nine patients (56.3%) experienced transient sensation of dryness of mouth, four of whom also experienced dryness of eyes. These may have been related to the study drug, but they may also have been related to withdrawal from pyridostigmine. Abdominal cramps and diarrhea, which are well recognized as a side effect of AChE inhibitors, were strikingly absent during treatment with Monarsen. 
Conclusions
Oral administration of Monarsen resulted in marked improvements in the severity of myasthenia gravis symptoms and signs. Most patients had improved QMGs on day 4 compared with baseline values (no pyridostigmine). Doses of pyridostigmine were not optimized, nonetheless, there was the impression that Monarsen might be more efficacious than pyridostigmine in many cases. The results of this open-label study must be viewed with caution. The effects seen, combined with the vital capacity and swallowing data, however, seem too consistent for the more erratic placebo effect and are much more consistent with a genuine pharmacological effect. Following these promising results, a phase II study is currently underway.
